Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05716516 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

STUDY02001740;22SCH740: Estradiol For ER+ Advanced Breast Cancer (ESTHER)

Study acronym: ESTHER
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv7
  2. Primary completion date: May 2026 to May 2027v6
  3. 2 versions Re-verified since Nov 13, 2023, no change to tracked fieldsv4-v5
  4. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of May 2023 to May 4, 2023
    v3
  5. Primary endpoint revised
    • Secondary endpoints: details revised at 4 of 4 entries
    • Study title shortened, about 11 words
    • Eligibility criteria shortened, about 4 words
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Determine whether subjects harboring ESR1-mutant/amplified breast cancer have a higher rate of clinical benefit from 17b-estradiol therapy than subjects with ESR1-wild-type breast cancer
Trial Details
NCT Number NCT05716516
Lead Sponsor Dartmouth-Hitchcock Medical Center
Conditions
(from sponsor)		 Metastatic Breast Cancer
Related terms Breast Neoplasms, Neoplasm Metastasis
Enrollment 36 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov